Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaticabtagene Autoleucel in Refractory AIHA
NCT07091370Phase 1Not yet recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of inaticabtagene autoleucel in autoimmune hemolytic anemia (AIHA), sponsored by Juventas Cell Therapy Ltd. Primary endpoints: Incidence of Treatment-related Adverse Events at 28 days and Recommended Phase II Dose at 28 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07091370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091370.